Q-omics provides the consensus-scored P4HA1 profile across patient tissues and cancer cell-line models. P4HA1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, P4HA1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, P4HA1 protein abundance shows 25,987 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where P4HA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P4HA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P4HA1 survival associations across molecular data types. P4HA1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P4HA1 RNA expression–survival associations across cancer types. High P4HA1 expression shows unfavorable associations in KIRP, MESO, UVM, KICH, HNSC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for P4HA1 RNA expression.
This table summarizes P4HA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for P4HA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P4HA1 shows higher tumor expression in HNSC, KIRC, STAD, COAD, LUAD and LUSC. The HNSC box plot shows higher P4HA1 RNA expression in tumor versus normal tissue (log2 FC = +2.273, t-test p < 0.001).
This table shows molecular features associated with P4HA1 in patient tissues and cancer cell lines. In patient samples, P4HA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, P4HA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
